PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-65.77%
Negative EBIT growth while TRAW is at 154.64%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-6.04%
Negative operating income growth while TRAW is at 154.64%. Joel Greenblatt would press for urgent turnaround measures.
-65.74%
Negative net income growth while TRAW stands at 154.35%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-47.67%
Negative EPS growth while TRAW is at 149.19%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-53.82%
Negative diluted EPS growth while TRAW is at 100.00%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
12.14%
Share count expansion well above TRAW's 10.48%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
7.50%
Slight or no buyback while TRAW is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
-13.29%
Negative OCF growth while TRAW is at 35.97%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-13.04%
Negative FCF growth while TRAW is at 35.97%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-24856.69%
Negative 10Y OCF/share CAGR while TRAW stands at 88.74%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-19589.97%
Negative 5Y OCF/share CAGR while TRAW is at 88.74%. Joel Greenblatt would question the firm’s operational model or cost structure.
63.13%
3Y OCF/share CAGR at 50-75% of TRAW's 88.74%. Martin Whitman would suspect weaker recent execution or product competitiveness.
-19587.84%
Negative 10Y net income/share CAGR while TRAW is at 119.26%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-19245.92%
Negative 5Y net income/share CAGR while TRAW is 119.26%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
62.10%
3Y net income/share CAGR 50-75% of TRAW's 119.26%. Martin Whitman might see a lagging edge in short-term profitability vs. the competitor.
30196.53%
10Y equity/share CAGR above 1.5x TRAW's 103.91%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
5954.03%
5Y equity/share CAGR above 1.5x TRAW's 103.91%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
827.17%
3Y equity/share CAGR above 1.5x TRAW's 103.91%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
6.14%
Positive asset growth while TRAW is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
-14.41%
We have a declining book value while TRAW shows 133.72%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-8.17%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
28.86%
We expand SG&A while TRAW cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.